NetworkNewsBreaks – Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) Secures $80.5 Million in Underwritten Public Offering
Arcturus Therapeutics Holdings (NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, has closed an underwritten public offering of 4,735,297 shares of its common stock, including 617,647 additional shares pursuant to the full exercise of the over-allotment granted to the underwriters. According to the update, Arcturus Therapeutics secured approximately $80.5 million in gross proceeds, with each of the shares sold at the public offering price of $17.00. The company intends to use the proceeds for working capital and general corporate purposes, which may include R&D and…







